A B S T R A C T Studies were carried out to determine if hyperaminoacidemia stimulates the secretion of pancreatic glucagon, and, if so, to evaluate the effect of endogenous and exogenous pancreozymin and of hyperglycemia upon this response. The intravenous administration to 16 dogs of 1 g/kg of a 10 amino acid mixture over a 60 min period raised amino nitrogen to a mean level of 13.5 mg/100 ml; mean pancreaticoduodenal vein insulin rose from 84 to 459 FLU/ml and glucagon from 1.1 to 2.7 mj&g/ml. Further augmentation of both insulin and glucagon secretion was achieved during hyperaminoacidemia by infusing pancreozymin.
Since endogenous pancreozymin is known to be stimulated by amino acids in the gut, it seemed possible that intraduodenal loading of amino acids would elicit a greater insulin and glucagon response than could be explained by the accompanying hyperaminoacidemia. The intraduodenal administration of 1 g/kg of the amino acid mixture was followed by substantial hyperinsulinemia and hyperglucagonemia, which frequently anticipated the hyperaminoacidemia, and in many of the dogs the ratio of hormone rise to amino nitrogen rise was greater after intraduodenal than after the intravenous route of amino acid administration in the same animal. Intraduodenal administration of amino acids did not cause measurable release of intestinal glucagon-like immunoreactivity into the mesenteric vein plasma.
Received for publication 20 May 1968. Hyperglycemia induced by constant glucose infusion prevented aminogenic hyperglucagonemia and even suppressed the augmenting action of pancreozymin; sudden termination of the infusion with continued amino acid infusion was associated with a striking rise in glucagon.
It is concluded (a) that hyperaminoacidemia stimulates pancreatic glucagon secretion, (b) that aminogenic hyperglucagonemia is augmented by the infusion of pancreozymin, (c) that intraduodenal administration of amino acids stimulates pancreatic glucagon secretion without measurable release of glucagon-like immunoreactivity into the mesenteric vein, and (d) that hyperglycemia prevents aminogenic hyperglucagonemia even during augmentation with pancreozymin. This conclusion suggests that the prevention of hypoglycemia during amino acid-induced insulin secretion may be an important function of glucagon.
INTRODUCTION
There is abundant experimental evidence which suggests that glucagon may be involved in the regulation of blood amino acid homeostasis. The administration of glucagon has been shown to lower plasma amino acids (1, 2) , presumably by increasing their uptake by the liver (3), and to increase the incorporation of the carbon skeletons of certain amino acids into glucose (4, 5) . Since recent studies with perfused rat livers indicate that this gluconeogenic effect occurs with physiologic
The Journal of Clinical Investigation Volume 47 1968 2305 (6) as well as with pharmacologic increments of perfusing glucagon, it would not, therefore, be surprising if endogenous pancreatic glucagon secretion were stimulated by hyperaminoacidemia. If so, increased secretion of pancreatic glucagon during hyperaminoacidemia might account for the fact that, during aminogenic insulin secretion, blood glucose concentration does not fall to a degree commensurate with the observed level of hyperinsulinemia (7) .
Assan, Rosselin, and Dolais (8) have already reported an apparent rise in peripheral plasma glucagon levels induced by hyperaminoacidemia; in 11 normal subjects given arginine by infusion a small increase averaging 0.33 m~ug/ml was observed, and a rise averaging 0.25 m/Ag/ml was observed 50 min after the ingestion of 500 g of meat. Similar results were reported in four subjects by Fajans, Floyd, Knopf, and Conn (9) . Our own group has reported striking rises in pancreaticoduodenal vein glucagon in 10 conscious dogs with indwelling catheters in the pancreaticoduodenal and mesenteric veins (10) . The preparation was employed not only because measurements of glucagon in peripheral plasma may fail to detect small but physiologically important increases in pancreatic glucagon secretion (11) , but also because such measurements cannot distinguish between pancreatogenous glucagon and enterogenous glucagon-like immunoreactivity (12) (13) (14) (15) , which probably comprises 70%o or more of the total circulating immunoreactivity in the fasting state (16) . During glucose absorption, for example, pancreatic glucagon secretion actually declines initially, but total immunoreactivity in the peripheral venous plasma rises; this rise is derived from gastrointestinal glucagon-like immunoreactivity (15) .
In the present study, the triply catheterized dog was employed to permit simultaneous measurement of both pancreaticoduodenal vein glucagon and mesenteric vein glucagon-like immunoreactivity. In this system the proximity of sampling to the hormone source permits the detection of changes which may not be fully discernible in the peripheral blood and makes possible the differentiation between pancreatic glucagon and enteric glucagonlike immunoreactivity. The study was designed to verify the small apparent rise in "glucagon," previously reported to accompany hyperaminoacidemia, to determine if such a rise is derived from pancreatic glucagon, from enteric glucagon-like immunoreactivity, or from both, and to determine the effects of exogenous and endogenous pancreozymin and of hyperglycemia upon islet hormone responses to hyperaminoacidemia.
METHODS
All experiments were conducted in male mongrel dogs surgically prepared as follows. 2 days or more before each experiment, a dog was anesthetized with Nembutal, and the abdomen was opened by midline incision. A small glass T cannula, connected with Teflon tubing, was inserted into the superior pancreaticoduodenal vein at a distance of about 3 cm from its junction with the portal vein. The tubing was fixed at the duodenum with a suture and exteriorized. A second Teflon catheter was inserted through the left jugular vein with its opening reposing in the inferior vena cava between the heart and the hepatic vein. In some dogs a third catheter was passed through a mesenteric radicle into a major superior mesenteric vein. Until the time of the experiment, the pancreatic vein catheter was infused continuously at a constant rate with diluted heparin-saline solution so as to deliver 100 U of heparin in a volume of 20 ml/hr. Each animal received a daily intramuscular injection of 600,000 U of penicillin G. Dogs were fed on a Purina Chow diet, composed of 54%o carbohydrate, 8%o fat, and 24% protein.
Recovery from the surgical procedure was uneventful in the majority of dogs. Only dogs that appeared to be in good health were employed for experiments. The appearance of either diarrhea, loss of appetite, weight loss in excess of 1.5 kg, a white blood cell count above 30,000, or elevation of body temperature above 104'F was regarded as grounds for disqualification from the study.
Dogs with a hematocrit of less than 35% were transfused on the day before the experiment. After completion of a series of experiments, each dog was sacrificed, and the position of the catheters and the patency of veins were checked. Dogs in which the pancreaticoduodenal vein was not patent were excluded from the study.
The amino acid mixture employed was identical in composition with that used by Floyd, Fajans, Conn, Knopf, and Rull (7): (19) , and glucagon was assayed by the previously described radioimmunoassay (20) as recently modified (21) . The antiglucagon antiserum employed was G128P, a serum which reacts with gastrointestinal glucagon-like immunoreactivity as well as with pancreatic glucagon.
When introduced into the assays in the concentrations encountered in plasma, the amino acid mixture did not affect either the glucagon or insulin radioimmunoassays. 1 
RESULTS
Effect of amino acid infusion. The 10 amino acid mixture was infused at a constant rate of 17 1 Schalch has suggested that the amino acids interfere with the immunoassay of glucagon in vitro, and that the reported rise in glucagon after amino acid infusion may be an artifact (personal communication). To determine the in vitro effect of the amino acid mixture upon the glucagon assay, the mixture was assayed in varying concentrations. No interference with the glucagon assay was observed at concentrations below 2%. Since, in these experiments, the highest plasma concentration of amino nitrogen measured was 26 mg/100 ml, which corresponds to only 260 mg/100 ml of amino adds, it seems improbable that hyperaminoacidemia could have influenced the glucagon measurements reported here. a | ZAMINO A 4g/Kg mg/kg of body weight per min for 60 min (a total dose of 1 g/kg) in a group of 16 dogs. Mean amino nitrogen concentration rose to a peak of 13.5 mg/100 ml (SEM + 0.6). The mean pancreaticoduodenal vein insulin level rose promptly from a base line value of 84 MU/ml (SEM ± 22) to a peak level of 459 MuU/mi (SEM + 66). Mean glucagon concentration in the pancreaticoduodenal vein rose simultaneously in somewhat parallel fashion, from a base line level of 1.1 mpg/ml (SEM + 0.1) to a peak value of 2.7 mpg/ml (SEM ± 0.4). The mean blood glucose concentration rose 4 mg/100 ml initially and subsequently declined 3 mg/100 ml (Fig. 1 a) . The individual results are recorded in Table I .
Since the levels of amino nitrogen in the foregoing experiments were considerably above the 5.4-10.4 mg/100 ml range reported by Floyd et al. (7) similar results were obtained, although the increase response to the 1.0 g/kg intravenous load appeared in glucagon was not statistically significant. Mean in Table I . This was followed by an elevation of insulin concentration rose to an early peak of 296 mean vena caval amino nitrogen to a peak level ,uU/ml, while mean glucagon rose concomitantly of 10.7 mg/100 ml. The mean pancreaticoduodenal to 2.6 mrg/ml. Mean plasma glucose rose 5 mg/ insulin concentration rose to a peak of 345 ,AU/ml 100 ml initially and later fell 4 mg/100 ml ( Fig. (SEM + 86) and glucagon rose to a peak of 2.1 1 b). The results of all experiments are presented mpg/ml (SEM 0.3) (Fig. 2) . The results of in Table II. individual intraduodenal experiments are recorded Effects of intraduodenal amino acid administra-in Table III * Amino N (mg/100 ml); Glucose (mg/100 ml); Glucagon (mpg/ml); Insulin (pU/ml).
gon after glucose loading first reported by Samols, significant increments above the value at zero time Marri, Tyler, and Marks (22) and by Lawrence occurred only in the pancreaticoduodenal vein (23) occurs in the absence of the pancreas and is plasma and indicated that the hyperglucagonemia probably derived from glucagon-like immuno-was largely, if not entirely, pancreatogenous. reactivity present in the gastrointestinal tract (15) . Effect of pancreozymin on islet hormone reTo examine the possibility of an intestinal contri-sponse to hyperaminoacidemia. Since the islet rebution to the apparent rise in plasma glucagon sponse observed during hyperaminoacidemia was which follows intraduodenal amino acid loading, qualitatively identical with that which follows infumesenteric venous plasma collected during absorp-sion of pancreozymin (21) , a hormone released tion of a 1.0 g/kg amino acid load was assayed during amino acid absorption (24) , it seemed of for glucagon. The results, illustrated in Fig. 3 , interest to determine if pancreozymin was capable reveal no significant measurable rise in mesenteric of augmenting the secretion of insulin and glucagon vein glucagon-like immunoreactivity; statistically during their stimulation by hyperaminoacidemia. Highly purified exogenous pancreozymin,2 infused at a rate of 8 Harper-Raper Units/min, caused in each of six experiments an immediate and sharp rise in the pancreaticoduodenal vein concentration of both hormones, already elevated by the hyperaminoacidemia. The most dramatic example is shown in Fig. 4 , and the results of all such experiments are recorded in Table IV Table II , were given 0.5 g/kg dose of amino acids adjusted to pH 4, the postprandial FIGuRE 3 Mean increments of glucagon in the pancreaticoduodenal, inferior vena caval, and mesenteric vein plasma after the intraduodenal administrataion of 1 g/kg of amino acid mixture in a group of eight dogs. A heavy dot on the mean curve indicates that this point differs significantly (P < 0.01) from the mean value at zero time. pH of gastric contents in dogs, through an intraduodenal tube which pointed cephalad and terminated in the upper portion of the duodenum. The mean level of amino nitrogen rose to a peak of 7.4 mg/100 ml. The mean insulin rose from a base line level of 57 to a peak of 148 juU/ml, and the mean glucagon level rose from 1.9 to 2.8 mpug/ml, even though in two of six dogs glucagon failed to rise at all. These results are recorded in Table V , and the mean response is shown in Fig. 5 . Despite the seemingly brisker initial hormone response relative to the amino nitrogen level, the results did not differ to a statistically significant degree from the results of the intravenous experiments (Table VI B) . Despite the lack of statistically significant evidence of enhancement of the hormonal response with intraduodenal administration, with the large intraduodenal load (1 g/kg) , the glucagon response per mg/100 ml rise in amino nitrogen to this route of administration exceeded the response to intravenous loading in 11 of 16 dogs, and the insulin response was greater in 6 of 16. With the smaller amino acid load (0.5 g/kg), the glucagon response to intraduodenal administration was greater in all six comparisons, and the insulin response was greater in three of six comparisons.
INSULliv
The ratios of hormone rise to amino nitrogen rise are recorded for all experiments in Tables VI A and B. The frequent occurrence of a seemingly greater hormonal response to intraduodenally administered amino acid at a lower amino nitrogen level makes it difficult to exclude augmentation from the gut. Furthermore, it should be pointed out that the abrupt rise in mean insulin concentration 5 min after the intraduodenal administration of amino acids and the similarly rapid increase in mean glucagon concentration at 5 and 10 min anticipate the appearance of hyperaminoacidemia (Figs. 2 and 5 ) and also are compatible with enterohumoral stimulation of the islets.
Effect of hyperglycemia on aminogenic hyperglucagonemia. It has been reported previously that hyperglycemia suppresses glucagon secretion both in the fasting state (15) and during insulin hypoglycemia (25) , but the effect of hyperglycemia-upon aminogenic hyperglucagonemia has not been tested. Therefore, in a group of five dogs, glucose was infused at a constant rate of 200 mg/min, for at least 90 min before and during the intravenous infusion of amino acids, administered at a rate of 100 mg/min. The pancreaticoduodenal vein concentration of glucagon, which had declined during hyperglycemia from a mean . 0
M N U T E S FIGURE 6 The effect of hyperglycemia upon the insulin and glucagon response to intravenously administered amino acid mixture and pancreozymin infusion (PZ).
sion was continued. Blood glucose fell from an average of 161 to 82 mg/100 ml, and under these conditions, mean glucagon concentration rose from 0.7 to 3.9 mug/ml. Fig. 6 provides a representative example of this type of experiment; hyperglycemic suppression of glucagon was evident at first, and even the powerful augmenting action of pancreozymin infusion upon glucagon secretion was nullified during hyperglycemia of this magnitude. However, when the glucose infusion was terminated, with continued amino acid infusion, a remarkable rise in pancreatic glucagon secretion accompanied the decline in the blood glucose concentration, and at this point, the infusion of pancreozymin further augmented the striking hyperglucagonemia.
DISCUSSION
The results indicate that in dogs hyperamino- Of considerable physiologic interest is the demonstration that hyperglycemia in excess of 160 mg/100 ml completely prevented both the aminogenic hyperglucagonemia and its augmentation by pancreozymin. However, when the glucose infusion was terminated and blood glucose fell towards normal, glucagon secretion rose to unprecedentedly high levels during the continuing hyperaminoacidemia, and this rise was further augmented by pancreozymin. The ability of hyperglycemia, which does not prevent aminogenic hypersomatotropinemia (26) , to suppress completely the most potent known stimulus to glucagon secretion, combined infusion of amino acids and pancreozymin, suggests that the function of aminogenic glucagon secretion may be to prevent hypoglycemia (27) rather than to lower amino acid levels, and that glucagon secretion is unnecessary when exogenous (27) .
